

Iqvia Holdings Inc. (IQV)

NYSE; other; SIC 8731, Services-Commercial Physical & Biological Research; CIK 0001478242

Iqvia Holdings Inc. IQV; other	
Grade	D  fourth fifth of 336 graded peers percentile 62.7; sampling error 2.6 points; lower is stronger
Rank	211 of 336
Profitability	C/D  percentile 58.4
Solvency	C  percentile 47.6
Growth and financing	C  percentile 49.7
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$29.9B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active
Inputs computable	10 of 14
Graded from	filings received through Feb 17, 2026 234 days before the rescans; latest periodic filing 10-Q received Jul 28, 2026
Last close	\$259.10 2026-10-08; market equity \$43.2B
Price used in grade	None



D, the sloth
fourth fifth of its sector; letters are fifths of the 336 graded peers


Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: D from Feb 21, 2023, C from Mar 21, 2023, E from Feb 21, 2024

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 17, 2026

IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence[®] to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI[®], advanced analytics, the latest technologies and extensive domain expertise.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 58.4						
Gross profitability		not computable	27.1%			one or more required annual facts are missing
Return on invested capital		not computable	10.0%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(4.6%)	(5.9%)	58.4	506	2025-12-31
Gross margin stability, five years		not computable	2.2 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 47.6						
Twelve-month failure probability		0.03%	0.04%	20.5	45	2026-03-31
Altman Z double-prime		1.13	2.05	50.1	386	2025-12-31
Net debt to EBITDA		not computable	2.52x			latest aligned inputs end 2017-12-31; latest annual assets end 2025-12-31
Interest coverage		2.99x	2.18x	41.4	88	2025-12-31
Current ratio		0.75x	1.32x	78.6	506	2025-12-31
Growth and financing, sleeve percentile 49.7						
Revenue growth, three-year compound		4.2%	5.1%	51.0	403	2025-12-31
Free cash flow growth, three-year compound		8.9%	8.7%	47.9	220	2025-12-31
Reinvestment rate		(81.8%)	11.9%	84.7	190	2025-12-31
Asset growth, three years		5.7%	4.1%	41.4	438	2025-12-31
Net share issuance, one year		(3.6%)	(0.4%)	23.4	356	2026-02-06

Among 336 peers

other; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
206	Cbiz, Inc. (CBZ)	61.2	C/D	
207	United Parcel Service Inc. (UPS)	61.5	C/D	
208	TransUnion (TRU)	61.8	C/D	
209	HF Sinclair Corp. (DINO)	62.1	C/D	

210	Izea Worldwide, Inc. (IZEA)	62.4	C/D fortress balance sheet
211	Iqvia Holdings Inc. (IQV) <	62.7	D
212	Corpay, Inc. (CPAY)	63.0	D
213	Marriott International Inc. (MAR)	63.3	D
214	DHI Group, Inc. (DHX)	63.6	D
215	Bright Horizons Family Solutions Inc. (BFAM)	63.9	D
216	Walt Disney Co. (DIS)	64.2	D

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	37.5%	2.0%	77
Distance from 52-week high	(5.9%)	(26.8%)	88
EBIT to enterprise value	4.2%	4.4%	46
Free cash flow yield	4.7%	4.1%	54
Book value to price	0.14	0.34	25
Sales to price	0.38	0.70	34
Composite equity issuance, five years	(13.6%)	(8.8%)	42
Relative strength against the sector, log excess return	0.17	(0.13)	77

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$1.9B
Operating cash flow, four quarters	\$2.7B
Months of runway	not finite
Days since last periodic filing	73 (10-Q received Jul 28, 2026)
Median daily dollar volume, 63 sessions	\$320.8M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	\$665.0M	2017-12-31	2020-02-18	10-K	0001564590-20-004901
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromDiscontinuedOperations	\$814.0M	2017-12-31	2020-02-18	10-K	0001564590-20-004901
3	income tax	us-gaap:IncomeTaxExpenseBenefit	-\$992.0M	2017-12-31	2020-02-18	10-K	0001564590-20-004901
4	total debt	us-gaap:LongTermDebt	\$10.3B	2017-12-31	2018-02-16	10-K	0001564590-18-002340
5	book equity	us-gaap:StockholdersEquity	\$8.0B	2017-12-31	2019-02-19	10-K	0001564590-19-003180
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$959.0M	2017-12-31	2019-02-19	10-K	0001564590-19-003180
7	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	\$7.1B	2016-12-31	2017-02-16	10-K	0001193125-17-046709
8	book equity	us-gaap:StockholdersEquity	\$8.6B	2016-12-31	2018-02-16	10-K	0001564590-18-002340
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$1.2B	2016-12-31	2019-02-19	10-K	0001564590-19-003180
10	net income	us-gaap:NetIncomeLoss	\$1.4B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.7B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
12	assets	us-gaap:Assets	\$29.9B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
13	assets	us-gaap:Assets	\$26.9B	2024-12-31	2026-02-17	10-K	0001628280-26-008322

14	current assets	us-gaap:AssetsCurrent	\$6.2B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
15	current liabilities	us-gaap:LiabilitiesCurrent	\$8.3B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	\$7.4B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
17	operating income	us-gaap:OperatingIncomeLoss	\$2.2B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
18	book equity	us-gaap:StockholdersEquity	\$6.5B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
19	liabilities	us-gaap:Liabilities	\$23.3B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
20	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$1.0B	2017-12-31	2020-02-18	10-K	0001564590-20-004901
21	interest expense	us-gaap:InterestExpense	\$729.0M	2025-12-31	2026-02-17	10-K	0001628280-26-008322
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$16.3B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$15.4B	2024-12-31	2026-02-17	10-K	0001628280-26-008322
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$15.0B	2023-12-31	2026-02-17	10-K	0001628280-26-008322
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$14.4B	2022-12-31	2025-02-13	10-K	0001478242-25-000045
26	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$603.0M	2025-12-31	2026-02-17	10-K	0001628280-26-008322
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.7B	2024-12-31	2026-02-17	10-K	0001628280-26-008322
28	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$602.0M	2024-12-31	2026-02-17	10-K	0001628280-26-008322
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.1B	2023-12-31	2026-02-17	10-K	0001628280-26-008322
30	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$649.0M	2023-12-31	2026-02-17	10-K	0001628280-26-008322
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$2.3B	2022-12-31	2025-02-13	10-K	0001478242-25-000045
32	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	\$674.0M	2022-12-31	2025-02-13	10-K	0001478242-25-000045
33	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$1.1B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
34	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	\$1.6B	2025-12-31	2026-02-17	10-K	0001628280-26-008322
35	income tax	us-gaap:IncomeTaxExpenseBenefit	\$252.0M	2025-12-31	2026-02-17	10-K	0001628280-26-008322
36	current assets	us-gaap:AssetsCurrent	\$5.8B	2024-12-31	2026-02-17	10-K	0001628280-26-008322
37	current liabilities	us-gaap:LiabilitiesCurrent	\$7.0B	2024-12-31	2026-02-17	10-K	0001628280-26-008322
38	assets	us-gaap:Assets	\$26.7B	2023-12-31	2025-02-13	10-K	0001478242-25-000045
39	assets	us-gaap:Assets	\$25.3B	2022-12-31	2024-02-15	10-K	0001478242-24-000038
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	169,700,000	2026-02-06	2026-02-17	10-K	0001628280-26-008322
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	176,100,000	2025-02-05	2025-02-13	10-K	0001478242-25-000045